Details for Patent: 10,478,494
✉ Email this page to a colleague
Which drugs does patent 10,478,494 protect, and when does it expire?
Patent 10,478,494 protects BALVERSA and is included in one NDA.
This patent has twenty-nine patent family members in twenty-five countries.
Summary for Patent: 10,478,494
Title: | FGFR/PD-1 combination therapy for the treatment of cancer |
Abstract: | Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient. |
Inventor(s): | Karkera Jayaprakash, Platero Suso Jesus, Verona Raluca, Lorenzi Matthew V. |
Assignee: | ASTEX THERAPEUTICS LTD |
Application Number: | US15079136 |
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,478,494
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PRIOR PD-1 OR PD-L1 INHIBITOR THERAPY | ⤷ Sign Up | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PRIOR PD-1 OR PD-L1 INHIBITOR THERAPY | ⤷ Sign Up | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PRIOR PD-1 OR PD-L1 INHIBITOR THERAPY | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,478,494
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 104172 | ⤷ Sign Up | |||
Australia | 2016243917 | ⤷ Sign Up | |||
Australia | 2022201060 | ⤷ Sign Up | |||
Brazil | 112017020973 | ⤷ Sign Up | |||
Canada | 2981603 | ⤷ Sign Up | |||
Chile | 2017002481 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |